The whole-body scan company is launching a research network with 50+ institutions. Early findings come with some big open ...
The company added hormone therapy to its platform and released IBS results from nearly 16,000 members, with caveats attached.
All three Phase 3 trials of the weekly shot ribupatide have finished enrolling, and the head-to-head against semaglutide is ...
Patent cliffs and falling R&D productivity push the biggest players toward other people's science – our report puts numbers ...
Monte Rosa’s NEK7-targeting drug pulled several heart-risk biomarkers toward healthy levels in 108 people with obesity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results